Suppr超能文献

上海乳腺癌研究中激素相关特征与雌激素受体/孕激素受体状态的乳腺癌风险之间的关联。

Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study.

机构信息

Vanderbilt Epidemiology Center, Institute of Medicine and Public Health, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 600, Nashville, TN 37203-1738, USA.

出版信息

Am J Epidemiol. 2011 Sep 15;174(6):661-71. doi: 10.1093/aje/kwr145. Epub 2011 Jul 18.

Abstract

Etiologic differences between subtypes of breast cancer defined by estrogen receptor (ER) and progesterone receptor (PR) status are not well understood. The authors evaluated associations of hormone-related factors with breast cancer subtypes in a population-based case-control study involving 1,409 ER-positive (ER+)/PR-positive (PR+) cases, 712 ER-negative (ER-)/PR-negative (PR-) cases, 301 ER+/PR- cases, 254 ER-/PR+ cases, and 3,474 controls aged 20-70 years in Shanghai, China (phase I, 1996-1998; phase II, 2002-2005). Polytomous logistic regression and Wald tests for heterogeneity across subtypes were conducted. Breast cancer risks associated with age at menarche, age at menopause, breastfeeding, age at first livebirth, waist-to-hip ratio, and oral contraceptive use did not differ by hormone receptor status. Among postmenopausal women, higher parity (≥2 children vs. 1) was associated with reduced risk (odds ratio (OR) = 0.69, 95% confidence interval (CI): 0.52, 0.91) and higher body mass index (BMI; weight (kg)/height (m)(2)) with increased risk (highest quartile: OR = 2.40, 95% CI: 1.65, 3.47) of the ER+/PR+ subtype but was unrelated to the ER-/PR- subtype (for parity, P(heterogeneity) = 0.02; for BMI, P(heterogeneity) < 0.01). Hormone replacement therapy (OR = 2.25, 95% CI: 1.40, 3.62) and alcohol consumption (OR = 1.59, 95% CI: 1.01, 2.51) appeared to be preferentially associated with the ER+/PR- subtype. These findings indicate that BMI, parity, hormone replacement therapy, and alcohol consumption may play different roles in subtypes of breast cancer. More research is needed to better understand the etiology of 2 relatively rare subtypes, ER+/PR- tumors and ER-/PR+ tumors.

摘要

雌激素受体(ER)和孕激素受体(PR)状态定义的乳腺癌亚型之间的病因学差异尚不清楚。作者在中国上海进行了一项基于人群的病例对照研究,该研究涉及 1409 例 ER 阳性(ER+)/PR 阳性(PR+)病例、712 例 ER 阴性(ER-)/PR 阴性(PR-)病例、301 例 ER+/PR-病例、254 例 ER-/PR+病例和 3474 例年龄在 20-70 岁的对照者(I 期,1996-1998 年;II 期,2002-2005 年)。采用多分类逻辑回归和 Wald 检验进行亚型间的异质性检验。与激素受体状态无关的是,月经初潮年龄、绝经年龄、母乳喂养、初产年龄、腰围与臀围比值和口服避孕药使用与乳腺癌风险的关系。在绝经后妇女中,更高的产次(≥2 个孩子 vs. 1 个孩子)与 ER+/PR+亚型的风险降低相关(比值比(OR)=0.69,95%置信区间(CI):0.52,0.91),更高的体重指数(BMI;体重(kg)/身高(m)(2))与 ER+/PR+亚型的风险增加相关(最高四分位数:OR=2.40,95%CI:1.65,3.47),但与 ER-/PR-亚型无关(对于产次,P(异质性)=0.02;对于 BMI,P(异质性)<0.01)。激素替代疗法(OR=2.25,95%CI:1.40,3.62)和饮酒(OR=1.59,95%CI:1.01,2.51)似乎与 ER+/PR-亚型优先相关。这些发现表明,BMI、产次、激素替代疗法和饮酒可能在乳腺癌的不同亚型中发挥不同的作用。需要进一步的研究来更好地了解 2 种相对罕见的亚型(ER+/PR-肿瘤和 ER-/PR+肿瘤)的病因。

相似文献

8
Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status.
Cancer Detect Prev. 2005;29(5):419-26. doi: 10.1016/j.cdp.2005.07.004. Epub 2005 Sep 23.
10
Relationship of established risk factors with breast cancer subtypes.
Cancer Med. 2021 Sep;10(18):6456-6467. doi: 10.1002/cam4.4158. Epub 2021 Aug 31.

引用本文的文献

1
Comparison Of Risk Factors and Clinicopathological Features Between Pre- and Post-Menopausal Patients with Breast Cancer.
Niger Med J. 2025 Jan 10;65(6):1008-1015. doi: 10.60787/nmj.v65i6.548. eCollection 2024 Nov-Dec.
2
The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients.
Turk J Med Sci. 2023 Nov 18;54(1):229-238. doi: 10.55730/1300-0144.5784. eCollection 2024.
4
Breast cancer risk factors and mammographic density among 12518 average-risk women in rural China.
BMC Cancer. 2023 Oct 9;23(1):952. doi: 10.1186/s12885-023-11444-7.
5
Analysis on Incidence and Mortality Trends and Age-Period-Cohort of Breast Cancer in Chinese Women from 1990 to 2019.
Int J Environ Res Public Health. 2023 Jan 1;20(1):826. doi: 10.3390/ijerph20010826.

本文引用的文献

2
Soy product and isoflavone intake and breast cancer risk defined by hormone receptor status.
Cancer Sci. 2010 Feb;101(2):501-7. doi: 10.1111/j.1349-7006.2009.01376.x. Epub 2009 Sep 29.
3
Menopausal hormone therapy and risk of clinical breast cancer subtypes.
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1188-96. doi: 10.1158/1055-9965.EPI-09-0002. Epub 2009 Mar 31.
4
Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study.
Am J Epidemiol. 2009 May 15;169(10):1251-9. doi: 10.1093/aje/kwp036. Epub 2009 Mar 24.
5
Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin.
Obesity (Silver Spring). 2009 May;17(5):1070-6. doi: 10.1038/oby.2008.641. Epub 2009 Jan 29.
6
Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China.
Breast Cancer Res Treat. 2009 Sep;117(2):409-16. doi: 10.1007/s10549-008-0303-z. Epub 2009 Jan 20.
8
Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort.
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3150-60. doi: 10.1158/1055-9965.EPI-08-0435.
10
Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study.
Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1723-30. doi: 10.1158/1055-9965.EPI-07-2824.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验